qRT‐PCR analysis revealed significant decreases in AD biomarkers (IL‐4, IL‐13, IL‐22, IL‐31, CCL17, and TSLP) and inflammatory cytokines (TNF‐α, IFN‐γ, IL‐6, and IL‐1β) in the iMSC secretome treatment groups (5 and 20 mg/mL) compared to the DNCB group (p  < 0.05) (Figure 5A). This evidence concerns the gene IL22 and Alzheimer disease.